Enliven Therapeutics Inc
ELVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.36B
Close$
$1.74
96.3% downside
Current Fair Value
96.3% downsideOvervalued by 96.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.36 Billion |
|---|---|
| Enterprise Value | $3.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.25 |
| Outstanding Shares | 66,171,581 |
Return
| Return on Equity | -11.83% |
|---|---|
| Return on Assets | -11.64% |
| Return on Invested Capital | -12.81% |
Valuation & Multiples
| P/E Ratio | -28.64 |
|---|---|
| PEG | -101.48 |
| Price to Sales | - |
| Price to Book Ratio | 3.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -28.08 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6484▲ 33.01% |
|---|---|
| Total Calls | 184,000▼ 85.08% |
| Total Puts | 119,300▼ 69.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 121.88%▲ 22.53% |
|---|---|
| Total Invested | $4.08B▲ 68.16% |
| Investors Holding | 222▲ 42.00% |
ESG Score
No data
About Enliven Therapeutics Inc
41 employees